2026年上半年信息
兴科蓉医药公告显示，报告期内公司实现营收10.33亿元，同比下降13.7%。同期净利润为19.9百万元，较上年同期减少4.5百万元。公司毛利率由上年同期的10.9%提升至12.0%。经营活动所得现金流量净额从上年同期的-13.3百万元增至1.19亿元。
成本结构方面，销售及分销开支同比增加9.0百万元至37.4百万元，主要来自营销及推广费用投入增长；行政开支相比上年同期略增2.1百万元，达41.6百万元，主要由于其他杂项成本上升所致。
业务分项
公司核心的进口药品销售业务实现收入10.26亿元，同比减少13.5%。管理层提及，整体医药及血液制品市场竞争愈发激烈，加之终端需求释放趋缓、产品售价承压、采购成本下降等多重因素，令该板块出现下滑。
医美服务板块在2026年上半年实现收入6.8百万元，同比下降28.4%。公告提及，这主要受整体经济下行导致的客流减少及人均消费下降等影响。从利润结构看，该板块仍致力于持续加大研发投入并丰富产品管线，以期为未来业绩增长提供新动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.